Dynamis Therapeutics Secures $500,000 Investment and NIH SBIR Grant

Share Article

Funds to be Used to Develop Agents to Treat Chronic Inflammatory Disorders and Promote Healthy Aging

“The award of this grant recognizes the key role of Aging Factor in the development of complications associated with diabetes,” said Annette Tobia, PhD, President and CEO, Dynamis Therapeutics.

Dynamis Therapeutics, Inc., a privately held company specializing in consumer, OTC and pharmaceutical products that promote healthy aging, announced today that it has raised $500,000 from an angel investor and received an NIH SBIR grant to discover small molecule inhibitors of diabetic complications which represent accelerated aging diseases. The Dynamis technology involves inhibiting the production of a highly reactive sugar, 3-deoxyglucosone, an Aging Factor, due to its role in chronic inflammation, oxidative stress and formation of advanced glycation end products (AGEs), all of which are associated with unhealthy aging and diabetic complications.

The sponsoring agency for the grant is The National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) and the research will be conducted in collaboration with the Lankenau Institute for Medical Research (LIMR) in Wynnewood, PA. The grant will focus screening the LIMR library of chemical compounds for novel inhibitors of the enzyme fructosamine-3-kinase that plays a major role in the formation of Aging Factor.

“The award of this grant recognizes the key role of Aging Factor in the development of complications associated with diabetes,” said Annette Tobia, PhD, President and CEO, Dynamis Therapeutics. “It provides support for the development of therapeutics that may interfere with the onset of pathologies associated with elevated levels of glucose such as nephropathy, retinopathy and neuropathy. The enzyme was discovered at the Fox Chase Cancer Center in Philadelphia, PA.”

About Dynamis Therapeutics, Inc.
Dynamis Therapeutics, Inc. is a biopharmaceutical company that is developing proprietary new drugs to treat chronic inflammatory disease and promote healthy aging. Its drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone (3DG). Scientific evidence, including research at the Fox Chase Cancer Center, suggests that elevated 3DG causes metabolic, neurological, and dermatological diseases, ranging from diabetic retinopathy (blindness) and nephropathy (kidney disease) to inflammatory skin conditions and aging. The Company’s first medical products are drugs against dry eye and the complications of diabetes.

For more information contact:
Brad Zerler, Ph.D.
Dynamis Therapeutics, Inc.
484-919-0465

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ginny Simon
Project Marketing, Inc.
610-889-2036
Email >